Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 68

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 68
---
 non-dilutively as possible, for example in the form of royalty or debt-based funding or funding from non-profit groups interested in tick-borne diseases. There is no assurance that funds will be available on acceptable terms, or that additional dilutive funding will not be required.

| 38 | Velez                                                    
 et al 2021 - Lancet Child Adolesc Health 2022; 6: 86–95. |

<div align='center'>9</div>

Intellectual Property We are co-owners, with the U.S. Army, of patents in the United States and certain foreign jurisdictions directed toward use of Tafenoquine for malaria and have obtained an exclusive worldwide license from the U.S. Army to practice these inventions. We also have an exclusive worldwide license to use manufacturing information and non-clinical and clinical data that the U.S. Army possesses relating to use of Tafenoquine for all therapeutic applications and uses excluding radical cure of symptomatic vivax malaria. We have submitted patent applications in the United States and certain foreign jurisdictions for use of Tafenoquine for COVID-19, fungal lung infections, tick-borne diseases, and other infectious and non-infectious diseases in which induction of host cytokines/inflammation is a component of the disease process. The United States Patent and Trademark Office (“USPTO”) issued our first COVID-19 patent for Tafenoquine in 2023. We have optioned or licensed patents involving Celgosivir for the treatment and prevention of Dengue (from the National University of Singapore), COVID-19 & Zika (Florida State University), and have pending patent applications related to Celgosivir for RSV. We have optioned or own manufacturing methods related to Celgosivir. A detailed list of our intellectual property is as follows: Patents

| Title                                                                                 |     |       Patent 
          No. |     | Country   |     | Status  |     | US          
 Patent Date |     | Application 
 No.         |                  |     | Estimated/     
 Anticipated    
 Expiration     
 Date           |
| Dosing                                                                                
 Regimen For Use Of Celgosivir As An Antiviral Therapeutic For Dengue Virus Infections |     |   2013203400 |     | Australia |     | Granted |     |             |     |             |      2013203400+ |     | 10-April-2033* |
| Novel                                                                                 
 Dosing Regimens Of